Curis Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Curis han disminuido a una tasa media anual de -12.7%, mientras que en la industria Biotechs los beneficios crecieron en un 19% anualmente. Los ingresos han ido disminuyendo a una tasa media de 0.3% al año.

Información clave

-12.7%

Tasa de crecimiento de los beneficios

16.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	-0.3%
Rentabilidad financiera	n/a
Margen neto	-468.2%
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Aug 07

Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

Aug 05

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 03

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Dec 26

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Aug 18

Curis: Asymmetric Risk And Reward

Jul 17

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Mar 28

Checking In On Curis

Dec 15

Companies Like Curis (NASDAQ:CRIS) Can Afford To Invest In Growth

Dec 04

We Think Curis (NASDAQ:CRIS) Can Afford To Drive Business Growth

Aug 29

Curis Inc.: Revisiting CA-4948 After Q2 Update

Aug 25

Curis, Inc. (NASDAQ:CRIS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$16.33

Mar 19

Desglose de ingresos y gastos

Cómo gana y gasta dinero Curis. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:CRIS Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 24	10	-48	19
31 Mar 24	10	-48	19
31 Dec 23	10	-47	19
30 Sep 23	10	-47	18
30 Jun 23	10	-48	18
31 Mar 23	10	-52	19
31 Dec 22	10	-57	20
30 Sep 22	10	-59	20
30 Jun 22	11	-57	20
31 Mar 22	11	-52	19
31 Dec 21	11	-45	17
30 Sep 21	11	-39	16
30 Jun 21	10	-34	14
31 Mar 21	10	-30	13
31 Dec 20	11	-30	12
30 Sep 20	11	-31	12
30 Jun 20	11	-31	12
31 Mar 20	11	-32	12
31 Dec 19	10	-32	12
30 Sep 19	9	-29	12
30 Jun 19	9	-30	13
31 Mar 19	10	-32	14
31 Dec 18	10	-33	15
30 Sep 18	11	-35	15
30 Jun 18	11	-43	14
31 Mar 18	10	-48	15
31 Dec 17	10	-53	14
30 Sep 17	9	-57	15
30 Jun 17	8	-70	16
31 Mar 17	8	-67	16
31 Dec 16	8	-60	16
30 Sep 16	7	-63	15
30 Jun 16	8	-40	13
31 Mar 16	8	-37	13
31 Dec 15	8	-59	13
30 Sep 15	8	-51	13
30 Jun 15	7	-51	13
31 Mar 15	10	-45	12
31 Dec 14	10	-19	12
30 Sep 14	9	-17	11
30 Jun 14	15	-14	12
31 Mar 14	15	-13	12
31 Dec 13	15	-12	11

Ingresos de calidad: CRIS actualmente no es rentable.

Margen de beneficios creciente: CRIS actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CRIS no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 12.7% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CRIS en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CRIS no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-2.3%).

Rentabilidad financiera

Alta ROE: El pasivo de CRIS supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Curis Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Recent updates

New minor risk - Shareholder dilution

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $12.099999 million.

Price target decreased by 9.1% to US$22.50

New minor risk - Share price stability

Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%

Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet

New major risk - Negative shareholders equity

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 14%

Curis, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Curis, Inc. Announces Additional Data from Take Aim Leukemia Study

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Curis, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target decreased by 22% to US$77.40

Curis, Inc., Annual General Meeting, May 21, 2024

Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates upgraded to US$6.06 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 28%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Curis, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Curis, Inc. (NASDAQ:CRIS) Stock Catapults 63% Though Its Price And Business Still Lag The Industry

Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study

New major risk - Share price stability

Price target increased by 18% to US$180

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

We're A Little Worried About Curis' (NASDAQ:CRIS) Cash Burn Rate

Curis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

We're Hopeful That Curis (NASDAQ:CRIS) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Curis (NASDAQ:CRIS) In A Good Position To Invest In Growth?

Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Price target increased to US$15.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.25

Curis, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Curis Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

Curis, Inc. Elects Anne E. Borgman as Class I Director

Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022

Will Curis (NASDAQ:CRIS) Spend Its Cash Wisely?

Curis, Inc. Announces That the U.S. Food and Drug Administration (FDA) Has Notified Curis That It May Resume Enrollment of Additional Patients in the Monotherapy Phase of the TakeAim Leukemia Study

FDA Lifts Partial Clinical Hold on the Takeaim Lymphoma Study of Emavusertib of Curis, Inc

Curis stock soars 34% as FDA lifts partial clinical hold on emavusertib's lymphoma study

Price target increased to US$17.67

Curis, Inc. Appoints Diantha Duvall as Chief Financial Officer, Treasurer, Assistant Secretary, Principal Financial Officer and Principal Accounting Officer of the Company Effective as of August 5, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Curis, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Curis: Asymmetric Risk And Reward

Curis, Inc. Announces Resignation of William Steinkrauss as Chief Administrative Officer, Effective from August 5, 2022

Curis, Inc.(NasdaqGM:CRIS) dropped from Russell 3000E Growth Index

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

Consensus EPS estimates fall by 14%

Price target increased to US$15.75

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$14.20

Curis, Inc., Annual General Meeting, May 26, 2022

Curis, Inc. Announces FDA Partial Clinical Hold for on the Company’s Takeaim Lymphoma Phase 1/2 Study

Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)

Here's Why We're Not Too Worried About Curis' (NASDAQ:CRIS) Cash Burn Situation

Curis, Inc. Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers